The recent clinical success of targeted therapies in melanoma directed at the oncogene
BRAF validates the concept of targeting oncogenes. The p16-cyclin D-CDK4/6 …

Cutaneous melanoma (CM) is a highly aggressive and drug resistant solid tumor, showing
an impressive metabolic plasticity modulated by oncogenic activation. In particular …

We have previously detected a large germ-line deletion, which included the entire
p15/CDKN2B-p16/CDKN2A-p14/ARF gene cluster, in the largest melanoma-neural system …

Although CDKN2A is well-known as a susceptibility gene for melanoma and pancreatic
cancer, germline variants have also been anecdotally associated with a broader range of …

The molecular mechanisms and biology of cellular senescence in human melanocytes are
discussed, including similarities to and differences from senescence in fibroblasts and other …

The p16 INK4a and p14 ARF tumor suppressor genes (TSGs) are encoded within the
CDKN2A locus on chromosome 9p21 and function as cell cycle regulatory proteins in the …

At the doses used clinically, chemotherapy is believed to kill melanoma by a final
common'mitochondrial'pathway that leads to apoptosis. Similarly, several natural defence …

To evaluate the mutational profiles associated with BRAF mutations in human melanoma,
we have studied BRAF, RAS, PTEN, TP53, CDKN2A and CDK4 genes and their expression …

Malignant melanoma originates in melanocytes, the pigment‐producing cells of the skin and
eye, and is one of the most deadly human cancers with no effective cure for metastatic …

Metastatic melanoma is an aggressive skin cancer that is notoriously resistant to current
cancer therapies. In human melanoma, nuclear factor‐kappa B (NF‐κB) is upregulated …